Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is expected to announce its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $9.20 million for the quarter.
Sunshine Biopharma Trading Down 7.1%
NASDAQ:SBFMW opened at $0.14 on Wednesday. The firm’s fifty day moving average price is $0.13 and its 200 day moving average price is $0.18. Sunshine Biopharma has a 1-year low of $0.05 and a 1-year high of $0.45.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Featured Articles
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
